Author

Domenico Cristi Corsi

Observed names: D. Corsi, D.C. Corsi

Institutions: Agostino Gemelli University Polyclinic, Ospedale Santa Maria della Misericordia di Rovigo, AULSS 5 Polesana

Observed institutions: Agostino Gemelli University Polyclinic, Fatebenefratelli Hospital, Ospedale Santa Maria della Misericordia di Rovigo, Ottawa Hospital Research Institute, AULSS 5 Polesana

OpenAlex ID: A5043440887

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

2014 · E. Bajetta, I. Floriani, et al. · Annals of Oncology · 92

Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial

2016 · S. Lonardi, A. Sobrero, et al. · Annals of Oncology · 59

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX

2017 · Jean-François Emile, Catherine Julié, et al. · European Journal of Cancer · 49

A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients

2025 · P.F. Conte, M.V. Dieci, et al. · Annals of Oncology · 19

Position paper of the Italian Association of Medical Oncology on the impact of COVID-19 on Italian oncology and the path forward: the 2021 Matera statement

2022 · G.D. Beretta, R. Casolino, et al. · ESMO Open · 5

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset

2015 · Josef Thaler, Richard Greil, et al. · Annals of Oncology · 4

Weekly gemcitabine (GEM) and 5-fluorouracil (5-FU) in pancreatic carcinoma. Phase I–II study

1999 · P. Tarantini, D.C. Corsi, et al. · European Journal of Cancer · 3

O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO

2016 · C. Antoniotti, C. Cremolini, et al. · Annals of Oncology · 2

222MO Tumor immune microenvironment and survival outcome following preoperative chemoradiotherapy in locally advanced rectal cancer: Results from the STAR-01 study cohort

2025 · F. Negri, L. Gnetti, et al. · Annals of Oncology

Prognostic value of neutrophil-lymphocite ratio in resected high risk colorectal cancer: An analysis of adjuvant TOSCA trial

2018 · F. Petrelli, G. Rosati, et al. · Annals of Oncology

2003 · Blanca Sinués, Ana Fanlo, et al. · Oncology

2003 · Blanca Sinués, Ana Fanlo, et al. · Oncology

Works count: 12

Citation count: 233

H-index: 5

I10-index: 4